Assembly Biosciences, Inc. ASMB NASDAQ

Assembly Biosciences, Inc. (ASMB) generated $-41.09M in operating cash flow for fiscal year 2025. After capital expenditures of $66K, free cash flow was $-41.16M.

Free cash flow margin was -56.9% of revenue. Cash conversion ratio was 6.71x, indicating earnings are backed by cash.

Criteria supported by this page:

• HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (50/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (10/100) — Cash conversion ratio was 6.71x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 59/100 with 4/7 criteria passed.